GNLX GENELUX Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1231457 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-95.3%
TTM net income YoY-5.6%
TTM EPS YoY18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-396,200.0%
Net margin-373,362.5%
FCF margin-270,112.5%
EBITDA margin-393,262.5%
Returns
ROE-130.6%
ROA-95.4%
ROIC (approx.)-180.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue4,762.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $8,000 | $8,000 | $170,000 | $11.07M |
| R&D expense | $19.85M | $19.00M | $12.77M | $9.08M |
| SG&A expense | $13.37M | $12.71M | $11.57M | $5.00M |
| Operating income | -$33.21M | -$31.70M | -$24.16M | -$3.01M |
| Interest expense | — | — | $173,000 | — |
| Income tax | — | — | — | $1.10M |
| Net income | -$32.15M | -$29.87M | -$28.30M | -$5.21M |
| EBITDA | -$32.97M | -$31.46M | -$23.67M | -$2.46M |
| EPS (basic) | -0.86 | -0.95 | -1.16 | -0.57 |
| EPS (diluted) | -0.86 | -0.95 | -1.16 | -0.57 |
| Weighted avg. shares (diluted) | 37.18M | 31.45M | 24.43M | 9.12M |
| Balance sheet | ||||
| Cash & equivalents | $5.33M | $8.56M | $9.42M | $397,000 |
| Short-term investments | — | $22.33M | $13.77M | — |
| Current assets | $15.13M | $31.55M | $24.20M | $1.89M |
| PP&E, net | $2.17M | $1.32M | $1.17M | $644,000 |
| Total assets | $19.03M | $34.72M | $27.89M | $5.53M |
| Current liabilities | $6.22M | $6.90M | $6.55M | $31.63M |
| Short-term debt | — | — | $900,000 | — |
| Total liabilities | $7.48M | $8.44M | $8.42M | $41.31M |
| Shareholders' equity | $11.54M | $26.27M | $19.47M | -$35.78M |
| Shares outstanding | 38.14M | 34.73M | 26.79M | 9.13M |
| Cash flow statement | ||||
| Operating cash flow | -$25.27M | -$21.23M | -$20.27M | -$3.57M |
| Capital expenditure | $1.10M | $381,000 | $1.02M | $49,000 |
| Free cash flow | -$26.37M | -$21.61M | -$21.30M | -$3.62M |
| Investing cash flow | $12.14M | -$8.13M | -$14.72M | -$49,000 |
| Financing cash flow | $9.89M | $28.51M | $44.02M | -$478,000 |
| Depreciation & amortization | $244,000 | $235,000 | $499,000 | $553,000 |
| Stock-based compensation | $5.87M | $5.74M | $2.52M | $2.42M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.